Lynn Jehle, NP is a research investigator with Sutter East Bay Medical Foundation and Jordan Research and Education Institute at Alta Bates Summit Medical Center.
Sutter Health Research Enterprise
2850 Telegraph Ave
Suite 110
Berkeley, CA, 94705
(510) 204-8140
jehlel@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Biogen 257MS201 FUSION
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091
Investigators: Joanna A. Cooper M.D., Lynn Jehle NP
Status: Active, Recruiting
Contineum PTI-307-201 (VISTA)
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis (VISTA)
Investigators: Joanna A. Cooper M.D., Lynn Jehle NP, Deepak Soneji MD
Status: Active, Recruiting
GN41791
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE BLIND, DOUBLE DUMMY, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRES
Investigators: Matthew W. Arnold M.D., David Eric Collins MD, Joanna A. Cooper M.D., Aryn Earnhardt NP, Lynn Jehle NP, Antonio J Silva-Sayago MD, Bradley T Wrubel MD
Status: Active, Not Recruiting
Novartis CLOU064C12301 REMODEL-1
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Rela
Investigators: Matthew W. Arnold M.D., Joanna A. Cooper M.D., Lynn Jehle NP, Deepak Soneji MD, Bradley T Wrubel MD
Status: Active, Recruiting
Sanofi EFC17504
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary P
Investigators: Joanna A. Cooper M.D., Lynn Jehle NP
Status: Active, Recruiting